R R

What Is Ongentys?

Ongentys is a prescription medication containing opicapone, a catechol-O-methyltransferase inhibitor. It is used as an additional treatment alongside levodopa and carbidopa in patients with Parkinson's disease who experience OFF episodes. These episodes occur when motor symptoms return or worsen as the effects of levodopa decline. Ongentys helps extend the effects of levodopa but does not cure Parkinson's disease or replace regular dopaminergic treatment. It is administered orally once daily.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Ongentys?

Ongentys is a prescription medication containing opicapone, a catechol-O-methyltransferase inhibitor. It is used as an additional treatment alongside levodopa and carbidopa in patients with Parkinson's disease who experience OFF episodes. These episodes occur when motor symptoms return or worsen as the effects of levodopa decline. Ongentys helps extend the effects of levodopa but does not cure Parkinson's disease or replace regular dopaminergic treatment. It is administered orally once daily.

read more about ongentys ...

Copy this HTML:

Copy HTML Copied!

How Does Ongentys Work?

Ongentys blocks catechol-O-methyltransferase, or COMT, an enzyme involved in breaking down levodopa outside the brain. Inhibiting this enzyme increases levodopa availability and helps prolong its therapeutic effects. This can reduce the amount of time patients spend experiencing OFF episodes between levodopa doses. Ongentys does not directly replace dopamine or act as a dopamine agonist. Its effects depend on concurrent levodopa and carbidopa treatment.

Who Can Receive Ongentys Treatment?

Ongentys is approved as adjunctive treatment for patients with Parkinson's disease who experience OFF episodes while taking levodopa and carbidopa. A clinician evaluates the frequency of motor fluctuations, current medicines, liver function, and possible treatment interactions before prescribing it. Ongentys should not be used with nonselective monoamine oxidase inhibitors or in patients with certain catecholamine-secreting tumors. It is not approved as stand-alone treatment for Parkinson's disease.

How Should Ongentys Be Taken?

The recommended Ongentys dose is 50 mg orally once daily at bedtime. Patients should avoid food for one hour before and at least one hour after taking the medication. People with moderate liver impairment generally receive 25 mg daily, while those with severe liver impairment should avoid Ongentys. When a dose is missed, the next dose should be taken at the scheduled time the following day without doubling. Clinicians may adjust other Parkinson's medications if involuntary movements or related adverse effects develop.

What Are the Side Effects and Warnings of Ongentys?

Common adverse effects include involuntary movements, constipation, dizziness, and low blood pressure. Ongentys can cause or worsen dyskinesia by increasing levodopa exposure. Other serious concerns include hallucinations, psychotic behavior, sudden sleep episodes, and unusual compulsive urges. Some medications metabolized by COMT can interact with opicapone and affect cardiovascular function. Patients should report falls, severe dizziness, unusual behavior, or worsening involuntary movements. A clinician should supervise treatment changes and discontinuation.

Common Questions About Ongentys

Is Ongentys used for Parkinson's disease?

Yes. Ongentys is approved alongside levodopa and carbidopa to reduce OFF episodes in patients with Parkinson's disease.

Does Ongentys replace levodopa?

No. Ongentys works by slowing levodopa breakdown and is intended to be taken alongside levodopa and carbidopa.

When should Ongentys be taken?

Ongentys is taken once daily at bedtime, with no food for one hour before or at least one hour afterward.

Can Ongentys cause involuntary movements?

Yes. Ongentys can cause or worsen dyskinesia by increasing levodopa exposure. A clinician may adjust the Parkinson's treatment regimen if this occurs.

References

DailyMed - ONGENTYS (opicapone) capsule. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a511a531-112e-43f8-a43f-5334b0efe979. Date Accessed October 22, 2026.

Ongentys. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/ongentys. Date Accessed October 22, 2026.

Opicapone. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK575291/. Date Accessed October 22, 2026.

Opicapone. MedlinePlus. https://medlineplus.gov/druginfo/meds/a620059.html. Date Accessed October 22, 2026.

Opicapone. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Opicapone. Date Accessed October 22, 2026.